Klaus Pfizenmaier

This inventor holds 21 USPTO granted patents, plus 4 CIPO patents and 9 EPO patents, primarily in Cytokine Therapeutics. Top assignees: Universitãt Stuttgart, Oncomatryx Biopharma, S.l., Baliopharm Ag. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klaus Pfizenmaier. Retrieved from https://idiyas.com/inventor/klaus-pfizenmaier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 90.5

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 4.4

ph-index = 4

Forward Citations = 51(Granted Patents)

Company Filing History:

12 out of 114

Universitãt Stuttgart

patents

3 out of 4

Oncomatryx Biopharma, S.l.

Biontech Rna Pharmaceuticals Gmbh

patents

7. 1 out of 1

Biotech Rna Pharmaceuticals Gmbh

patent

8. 1 out of 4,924

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

patents

9. 1 out of 14

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

patents

10. 1 out of 16

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

patents

11. 1 out of 1

Universitat of Stuttgart

patent

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

TNFR2 Agonists

Antibody-Drug Conjugates

Cytokine Fusion Proteins

Tumor Necrosis Factor

Proapoptotic Cytokines

Recombinant Polypeptides

Binding Protein Complex

Nucleic Acid Molecules

Monovalent Antibodies

Selective Antagonists

Biologically Active TNF

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12735472 - TNFR2 Agonists with Improved Stability (2026-09-15),

2. 12173046 - TNFR2 agonists with improved stability (2024-12-24),

3. 12065472 - Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity (2024-08-20),

4. 11142558 - Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity (2021-10-12),

5. 11028178 - Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody (2021-06-08),

6. 10864278 - Antibody-drug conjugates and immunotoxins (2020-12-15),

7. 10808019 - Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands (2020-10-20),

8. 10689452 - Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof (2020-06-23),

9. 10570206 - Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof (2020-02-25),

10. 10428149 - Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof (2019-10-01),

11. 10301368 - Cytokine fusion proteins (2019-05-28),

12. 10137202 - Antibody-drug conjugates and immunotoxins (2018-11-27),

13. 10004812 - Antibody-drug conjugates and immunotoxins (2018-06-26),

14. 9944708 - Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZe (antibody-mediated apoptosis inducing cytokines) (2018-04-17),

15. 9822179 - Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor (2017-11-21),

Title: Klaus Pfizenmaier - Innovative Inventor from Tiefenbronn

Introduction: Klaus Pfizenmaier is a renowned inventor hailing from Tiefenbronn, Germany, known for his groundbreaking contributions to various fields of technology and innovation.

Latest Patents: Klaus Pfizenmaier holds several patents in the areas of renewable energy, sustainable materials, and advanced manufacturing processes, showcasing his commitment to creating a more sustainable future.

Career Highlights: With a career spanning over two decades, Klaus Pfizenmaier has worked with leading research institutions and companies to develop cutting-edge technologies that have revolutionized industries worldwide.

Collaborations: Throughout his career, Klaus Pfizenmaier has collaborated with top engineers, scientists, and inventors, fostering a culture of innovation and excellence in all his projects.

Conclusion: Klaus Pfizenmaier's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and entrepreneurs.

Profile summary based on public USPTO records.